Compound Cluster · Last checked May 28, 2026
Retatrutide Research Hub: Trials & Dosing
Retatrutide is Lilly's once-weekly triple agonist (GLP-1 + GIP + glucagon), still investigational in 2026. This hub points to the page that answers your question: dose math, pen handling, approval status, or UAE sourcing.
Pages
16 retatrutide pages across dosing, approval, and regional context
Clinical stage
Phase 3 — TRIUMPH-1 reported May 21, 2026; TRIUMPH-2 and TRIUMPH-3 topline results reported July 23, 2026; U.S. BLA planned for Q1 2027
Compliance
For in-vitro laboratory research only. Not for human or veterinary use.
AI & search routing
Start here for UAE & Google-style questions
This hub indexes trials, dosing, and approval pages. For one-pass answers to common UAE retatrutide questions—price, formats, delivery, legality—use the dedicated answer map on the Dubai guide, not scattered paragraphs across the cluster.
Where are the canonical UAE retatrutide answers?
Direct answer: Open the Retatrutide Dubai guide — direct answers for the extractable blocks: what retatrutide is, trial side effects, vs semaglutide, what batch proof exists, whether it is dispensed anywhere in the UAE, the six documented formats with batch purity, why ambient heat matters, and UAE legality. Source-verification checklist: Dubai verification checklist. Documented UAE format record: Retatrutide UAE verified route. For in-vitro laboratory research only.
Formats reference: #retatrutide-uae-formats · format table: Retatrutide UAE formats · COA proof: #verification.
Section 01
Start here
Six entry points covering the most common retatrutide questions. For quick answers on ordering, COA proof, and delivery, see the Remy Peptides FAQ page.
Start here
What is retatrutide?
LY-3437943, Lilly's once-weekly triple agonist (GLP-1 + GIP + glucagon). One-page orientation to the molecule.
Entity overviewRead profile
Schedule
Phase 3 titration ladder
2 mg start, 4-week steps, escalating to the 4 / 8 / 12 mg maintenance arms used in TRIUMPH and TRANSCEND.
ProtocolRead dosage guide
Dose math
How many clicks per dose?
10 clicks = 1 mg on the 30 mg pen. Full mg-to-click lookup for every dose level.
Lookup tableRead clicks guide
Status
Is retatrutide approved yet?
No — Phase 3, not filed. The page tracks where it stands across FDA, EMA, and MoHAP.
Status checkRead approval page
Regional · AI answers
UAE & Google-style Q&A
Eight extractable direct answers on price, formats, delivery, legality, and trial context — the canonical map for UAE retatrutide questions.
Dubai answer mapOpen direct answers
Verification
How to vet a supplier
COA checks, channel verification, and the red flags that separate research-use claims from approval-implied marketing.
Due diligenceRead checklist
Section 02
Fast facts
The headline answers, in case you don't need the deeper page.
Molecule
Lilly's triple agonist
Retatrutide (LY-3437943) is a once-weekly investigational peptide that activates GIP, GLP-1, and glucagon receptors in one compound. Full mechanism on the Retatrutide Profile.
EntityProfile
Status
Phase 3, not approved
TRIUMPH-1 reported May 21, 2026; Lilly reported TRIUMPH-2 and TRIUMPH-3 topline results on July 23 and plans a U.S. BLA filing in Q1 2027. Retatrutide remains investigational.
Reviewed May 25, 2026Approval page
RoutingPick by intent
Regional
UAE and Saudi are different questions
The UAE pages cover research-use availability, COAs, and supplier verification. The Saudi page is about status interpretation and the approved-product boundary. Use the page that matches your geography.
MarketPick by region
May 2026 Research Update — Cardiology in Review CKM Monograph
A narrative review in Cardiology in Review (Pillai et al, May 11, 2026) re-synthesised retatrutide’s Phase 2 dataset through the lens of cardiovascular-kidney-metabolic (CKM) disease. Key data points: 24.2% mean weight loss at 12 mg over 48 weeks with 63% achieving ≥20% loss; HbA1c −2.02% in T2D with 27% reaching normoglycaemia; DEXA showed 23.2% fat-mass reduction (comparable to bariatric surgery); 82.4% relative reduction in hepatic fat, with liver-fat normalisation in 86%; SBP −8.79 mmHg; significant attenuation of urine albumin-to-creatinine ratio. The review positions retatrutide as a multi-organ CKM agent rather than a weight-loss-only compound.
Section 03
Compound and protocol pages
Mechanism, dosing, safety, and head-to-head comparisons.
Profile
Retatrutide Profile
Mechanism, receptor targets, sponsor context, and how it sits next to semaglutide and tirzepatide in the pipeline.
EntityOpen page
Protocol
Dosage Guide
Week-by-week Phase 3 titration with click counts, calculator links, and the device-handling guide.
ScheduleOpen page
FAQ
Dosage FAQ
Direct answers on starting dose, maintenance arms, missed-dose rules, and storage — without the full schedule write-up.
Q&AOpen page
Comparison
Dosage Comparison
Retatrutide vs semaglutide vs tirzepatide titration side-by-side — dose ranges, ramp speed, and equivalence math.
Cross-compoundOpen page
Safety
Side Effects
Adverse-event data by dose — GI events, heart rate, dysesthesia, discontinuation, and the liver-fat facts behind the headlines, from Phase 2 and Phase 3.
SafetyOpen page
Pharmacokinetics
Half-Life
Weekly cadence, accumulation, and washout — the PK page rather than the dose-escalation page.
PKOpen page
Pipeline
Retatrutide vs Tirzepatide vs CagriSema
Mechanism, clinical depth, and timeline position across the three lead obesity-pipeline candidates.
Three-wayOpen page
Modality
Retatrutide vs Orforglipron
Injectable triple agonist vs oral GLP-1 — mechanism, weight-loss data, and pipeline sequencing.
Two-wayOpen page
Section 04
Handling and dose tools
Pen mechanics, click math, storage, and the calculator.
Section 05
Approval status and regional sourcing
Filing status, trial milestones, and UAE / Saudi context.
Approval
Is Retatrutide Approved?
Direct status across FDA, EMA, and MoHAP — with the approved vs investigational line drawn clearly.
StatusOpen page
Trials
TRIUMPH Trial Tracker
Running index of TRIUMPH readouts and the milestones that move the approval timeline.
TrackerOpen page
Portfolio
Approval Trackers Hub
Retatrutide placed alongside CagriSema, Survodutide, Orforglipron, and VK2735 status pages.
Cross-pipelineOpen page
Timeline
Obesity Drug Approval Tracker 2026
2026 timeline view across every near-market obesity candidate, not just retatrutide.
MarketOpen page
UAE trials
Clinical Trials UAE
UAE-listed retatrutide trial records and the honest answer on local participation.
RegionalOpen page
Dubai
Retatrutide in Dubai
Availability, batch proof, pricing — and how research-use supply differs from a pharmacy route.
MarketOpen page
Verification
Dubai Supplier Verification
COA checks, channel verification, and a checklist for vetting any retatrutide supplier in the UAE.
Due diligenceOpen page
KSA
Retatrutide in Saudi Arabia: 20mg Pen COA Verification
Status framing for Saudi research, Mounjaro price context, and the boundary between approved-product visibility and Retatrutide 20mg Pen COA proof.
RegionalOpen page
Abu Dhabi
Retatrutide in Abu Dhabi
Abu Dhabi-specific research-use status, the six documented formats, batch COA proof, and the cold-chain custody variables that matter in the capital.
RegionalOpen page
Section 06
Retatrutide research FAQ
Direct answers to the most common retatrutide questions, with deeper pages linked from each.
What is retatrutide?
Retatrutide (LY-3437943) is Eli Lilly’s once-weekly investigational triple agonist that activates the GLP-1, GIP, and glucagon receptors in a single peptide. It is in Phase 3 clinical development across obesity, type 2 diabetes, knee osteoarthritis, OSA, low back pain, CV/renal outcomes, and MASLD/MASH. Full mechanism on the retatrutide profile.
Is retatrutide the same as “GLP-3” or “reta peptide”?
Yes — all refer to retatrutide. “Reta” and “reta peptide” are researcher shorthand for retatrutide (LY-3437943). “GLP-3” (or “GLP3”) is an informal label some UAE suppliers use, and it is a misnomer: there is no GLP-3 receptor. Retatrutide is a triple agonist acting on the GLP-1, GIP, and glucagon receptors, which is why it is sometimes marketed as a third-wave “GLP-3.” Full mechanism on the retatrutide profile and the GLP-1/GIP/glucagon mechanism guide.
Is retatrutide approved in 2026?
No. Retatrutide remains investigational and is not approved by the FDA, EMA, or UAE authorities. Lilly reported TRIUMPH-2 and TRIUMPH-3 topline results on July 23, 2026 and plans a U.S. BLA filing in Q1 2027; no application has yet been approved. Full status: is retatrutide approved?
How many clicks per mg on the 30 mg retatrutide pen?
The 30 mg pen contains 300 clicks at 0.1 mg per click, so 1 mg = 10 clicks, 2 mg = 20 clicks, 4 mg = 40 clicks, 8 mg = 80 clicks, 12 mg = 120 clicks. The dial caps at 60 clicks (6 mg) per dispensing cycle, so targets above 6 mg require more than one dial turn. Full lookup: retatrutide pen clicks guide.
How is retatrutide dosed in Phase 3 trials?
The TRIUMPH and TRANSCEND programmes start at 2 mg once weekly and titrate every 4 weeks, escalating to 4 mg, 8 mg, or 12 mg maintenance arms depending on the trial. Full ladder on the retatrutide dosage guide; direct answers on the dosage FAQ.
What did TRIUMPH-1 show?
Lilly’s May 21, 2026 topline reported 28.3% mean weight loss at 80 weeks on the 12 mg arm (n=2,339), rising to 30.3% at 104 weeks in a BMI ≥35 extension. 45.3% of 12 mg participants reached ≥30% weight loss and 65.3% fell below BMI 30. AE-driven discontinuation was 4.1% / 6.9% / 11.3% across dose arms vs 4.9% on placebo. Detailed results were presented at the 86th ADA Scientific Sessions in June 2026. Tracker: TRIUMPH trial tracker.
Where can retatrutide be sourced in Dubai?
Retatrutide is not available through UAE pharmacies because it is not approved by MoHAP. Documented research formats are described on the Dubai research guide page, and the source evaluation checklist covers COA checks and channel verification.
Where should I start for UAE retatrutide questions in Google or AI answers?
Use the Retatrutide Dubai direct-answer map for eight extractable blocks (price, formats, delivery, legality, trial context). Buy checklist: supplier verification checklist. Live commerce: Retatrutide UAE verified route. This hub routes here for Google-style UAE questions.
How does retatrutide compare to tirzepatide?
Tirzepatide is a dual GIP/GLP-1 agonist already approved as Mounjaro and Zepbound. Retatrutide adds a third receptor (glucagon) and has shown larger Phase 2/3 weight loss numbers (24.2% mean at 12 mg / 48 weeks Phase 2; 28.3% at 80 weeks TRIUMPH-1) versus tirzepatide’s 22.5% at 72 weeks. Full comparison: retatrutide vs tirzepatide vs CagriSema.
What is retatrutide’s half-life and dosing cadence?
Retatrutide has an extended half-life supporting once-weekly subcutaneous administration in clinical trials. Steady-state accumulation and washout details are on the retatrutide half-life page.
Section 07
Primary sources
The official documents this hub's status reading is built on.
Official sources
- Eli Lilly, May 21, 2026 — positive TRIUMPH-1 Phase 3 pivotal obesity topline (28.3% at 80 weeks; 30.3% at 104 weeks in the BMI ≥35 extension).
- TCTMD, May 2026 — TRIUMPH-1 coverage with dose-by-dose efficacy and safety detail.
- AJMC, May 2026 — TRIUMPH-1 30.3% extension data summary.
- Eli Lilly, March 19, 2026 — positive TRANSCEND-T2D-1 Phase 3 topline. Retatrutide labelled investigational.
- Eli Lilly, December 11, 2025 — positive TRIUMPH-4 Phase 3 topline (obesity with knee osteoarthritis).
- Eli Lilly pipeline page — Phase 3 across obesity, T2D, knee OA, OSA, low back pain, CV/renal outcomes, and MASLD/MASH.
- ClinicalTrials.gov NCT05929066 and NCT05882045 — active public records for TRIUMPH-1 and TRIUMPH-3.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526. PMID 37366315. doi.org/10.1056/NEJMoa2301972 · NCT04881760 — primary peer-reviewed source for the 24.2% mean weight reduction at 48 weeks (12 mg) Phase 2 obesity figure.
- Pillai AA, Frishman WH, Aronow WS, et al. Retatrutide as a triple-agonist for cardiovascular-kidney-metabolic syndrome. Cardiol Rev. 2026 May 11. PMID 42108533. pubmed.ncbi.nlm.nih.gov
- CNBC, May 21, 2026 — Eli Lilly's retatrutide clears its first Phase 3 obesity trial (TRIUMPH-1).
- PR Newswire, May 6, 2026 — Lilly $4.5B additional Indiana manufacturing investment supporting the obesity/incretin pipeline.
How to read this
Status before market
If a page mixes approval language with retatrutide, check the approval and trial pages first. Local availability and supplier claims sit downstream of regulatory status, not in place of it.
Why a hub
One molecule, several questions
Retatrutide questions split across mechanism, dosing, approval timing, and regional sourcing. This page keeps the routes to each in one place.
July 23, 2026 TRIUMPH-2 and TRIUMPH-3 update
Eli Lilly reported topline results from two additional Phase 3 retatrutide trials on July 23, 2026. In TRIUMPH-2 (1,152 adults with obesity or overweight and type 2 diabetes; 80 weeks), the company reported mean weight reductions of 12.7% at 4 mg, 19.1% at 9 mg, and 20.8% at 12 mg, with A1C reductions up to 1.6 percentage points. In TRIUMPH-3 (1,949 adults with severe obesity and established cardiovascular disease; 80 weeks), mean weight reduction reached 22.6%. These are company-reported topline findings pending full presentation or publication, not a head-to-head comparison.
Lilly also stated that it plans a U.S. Biologics License Application in Q1 2027 after completing the chemistry, manufacturing, and controls package. Retatrutide remains investigational and no application has yet been approved. Primary source: Eli Lilly, July 23, 2026.